Johnson & Johnson announced it has asked the World Health Organization for emergency use listing for its single-dose Covid-19 vaccine.
The company said it had delivered the data from its late-stage trial to the WHO.
An emergency use listing would make the vaccine available in more than 190 countries, including multiple developing countries. If authorized, it would also allow J&J to supply the COVAX program – a global distribution and procurement agency that is helping manage Covid-19 vaccines for 190 participating countries.
In December, J&J came to an agreement with Gavi, the Vaccine Alliance, that is backing the COVAX program. If authorized, J&J expects to provide up to 500 million doses to COVAX through next year, the company said.
“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our unwavering commitment to equitable access,” Dr. Paul Stoffels, Johnson & Johnson’s vice chair of the executive committee and chief scientific officer, said in a news release. "If we are to end the global pandemic, life-saving innovations like vaccines must be within reach for all countries.”
J&J filed for a conditional marketing authorization application in the European Union on Monday.
Next Friday, the US Food and Drug Administration will consider the data the company submitted for an emergency use authorization of the vaccine in the United States. J&J has promised to deliver 100 million doses of its single-dose vaccine to the US by the end of June.
The Covid-19 vaccine’s efficacy against moderate and severe disease ranged from one country to another:
- 72% in the US
- 66% in Latin America
- 57% in South Africa
It was 66% effective globally. This was measured starting one month after the shot. The vaccine is 85% effective overall at preventing hospitalization and 100% at preventing death in all regions where it was tested.
Read more on the J&J vaccine: